ClinConnect ClinConnect Logo
Search / Trial NCT07056738

Prospective Exploratory Cohort Study on Ganglion Cell Degeneration in Retinitis Pigmentosa Patients

Launched by UNIVERSITY MEDICAL CENTER GOETTINGEN · Jun 29, 2025

Trial Information

Current as of July 23, 2025

Enrolling by invitation

Keywords

Retinitis Pigmentosa Ganglion Cells Inner Retina Optogenetics

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • genetically diagnosed Retintis pigmentosa
  • minimum age of 18 years (legal adult age in Germany)
  • patient consent for study participation
  • Exclusion Criteria:
  • lack of capacity to consent in participation of study (unconsciousness, mental capacity, mental illness)
  • reduced cooperation during imaging or examination
  • age under 18 years
  • presence of additional retinal diseases
  • insufficient imaging quality due to hazy media (cornea, lense)

About University Medical Center Goettingen

The University Medical Center Göttingen (UMG) is a leading academic institution in Germany, renowned for its commitment to advancing medical research and education. As a sponsor of clinical trials, UMG leverages its extensive expertise and state-of-the-art facilities to facilitate innovative research that aims to improve patient care and treatment outcomes. With a focus on interdisciplinary collaboration, UMG fosters partnerships across various medical fields, ensuring a comprehensive approach to clinical investigation. Its dedication to ethical standards and patient safety underscores its role in translating scientific discoveries into effective therapeutic solutions.

Locations

Göttingen, , Germany

Patients applied

0 patients applied

Trial Officials

Emilie Macé, Professor

Principal Investigator

Else Kroener Fresenius Center for Optogenetic Therapies, University Medical Center Goettingen

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported